The results showed that alterations in ZSWIM4 expression does not affect the cells' sensitivity to imatinib, as the drug effectively inhibited GIST cell survival and proliferation irrespective of ZSWIM4 levels although knockdown of ZSWIM4 expression and ZSWIM4 overexpression respectively increased or decreased cell survival, proliferation and cell cycle progression (Fig. 3A, B, C). The gene discussed is ZSWIM4; the disease is gastrointestinal stromal tumor.